Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention

Wataru Takagi, Toru Miyoshi, Masayuki Doi, Keisuke Okawa, Kazumasa Nosaka, Tomoyuki Nishibe, Naoaki Matsuo, Satoshi Hirohata, Hiroshi Itoh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Adipocyte fatty acid-binding protein (A-FABP) is expressed in both adipocytes and macrophages. Recent studies have shown that A-FABP is secreted by adipocytes and that the A-FABP concentration is associated with obesity, insulin resistance, and atherosclerosis. We have reported that the coronary atherosclerotic burden is associated with the serum A-FABP concentration. In the present study, we investigated whether the serum A-FABP concentration is associated with prognosis in patients with stable angina pectoris who have undergone percutaneous coronary intervention (PCI). Methods: This was a prospective single-center trial. In total, 130 patients with stable angina pectoris undergoing their first PCI were enrolled from August 2008 to July 2010 at Kagawa Prefectural Central Hospital. The primary endpoints were cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, revascularization, and hospitalization for heart failure. Results: During the follow-up (median, 50months; interquartile range, 23-66months), 49 cardiovascular events occurred. Kaplan-Meier analysis showed that the cumulative incidence of the primary endpoints in the high A-FABP group (median A-FABP concentration of ≥18.6ng/ml) was greater than that in the low A-FABP group. Cox analysis showed that the A-FABP concentration was an independent predictor of cardiovascular events adjusted for age and the presence of multi-vessel disease (hazard ratio, 1.03; 95% confidence interval, 1.01-1.04; p=0.01). Conclusion: The serum A-FABP concentration is associated with prognosis in patients with stable angina undergoing PCI, suggesting that the serum A-FABP concentration could be useful for risk assessment of secondary prevention. Trial registration: UMIN Clinical Trials Registry UMIN000029283(registration date: September 25, 2017), retrospectively registered.

Original languageEnglish
Article number258
JournalBMC Cardiovascular Disorders
Volume17
Issue number1
DOIs
Publication statusPublished - Oct 10 2017

Fingerprint

Fatty Acid-Binding Proteins
Stable Angina
Percutaneous Coronary Intervention
Adipocytes
Serum
Kaplan-Meier Estimate
Secondary Prevention
Registries
Insulin Resistance
Atherosclerosis

Keywords

  • Adipocyte
  • Coronary artery disease
  • Fatty acid
  • Risk factor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention. / Takagi, Wataru; Miyoshi, Toru; Doi, Masayuki; Okawa, Keisuke; Nosaka, Kazumasa; Nishibe, Tomoyuki; Matsuo, Naoaki; Hirohata, Satoshi; Itoh, Hiroshi.

In: BMC Cardiovascular Disorders, Vol. 17, No. 1, 258, 10.10.2017.

Research output: Contribution to journalArticle

@article{ade025c9bdef4ab6ad557a8802646161,
title = "Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention",
abstract = "Background: Adipocyte fatty acid-binding protein (A-FABP) is expressed in both adipocytes and macrophages. Recent studies have shown that A-FABP is secreted by adipocytes and that the A-FABP concentration is associated with obesity, insulin resistance, and atherosclerosis. We have reported that the coronary atherosclerotic burden is associated with the serum A-FABP concentration. In the present study, we investigated whether the serum A-FABP concentration is associated with prognosis in patients with stable angina pectoris who have undergone percutaneous coronary intervention (PCI). Methods: This was a prospective single-center trial. In total, 130 patients with stable angina pectoris undergoing their first PCI were enrolled from August 2008 to July 2010 at Kagawa Prefectural Central Hospital. The primary endpoints were cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, revascularization, and hospitalization for heart failure. Results: During the follow-up (median, 50months; interquartile range, 23-66months), 49 cardiovascular events occurred. Kaplan-Meier analysis showed that the cumulative incidence of the primary endpoints in the high A-FABP group (median A-FABP concentration of ≥18.6ng/ml) was greater than that in the low A-FABP group. Cox analysis showed that the A-FABP concentration was an independent predictor of cardiovascular events adjusted for age and the presence of multi-vessel disease (hazard ratio, 1.03; 95{\%} confidence interval, 1.01-1.04; p=0.01). Conclusion: The serum A-FABP concentration is associated with prognosis in patients with stable angina undergoing PCI, suggesting that the serum A-FABP concentration could be useful for risk assessment of secondary prevention. Trial registration: UMIN Clinical Trials Registry UMIN000029283(registration date: September 25, 2017), retrospectively registered.",
keywords = "Adipocyte, Coronary artery disease, Fatty acid, Risk factor",
author = "Wataru Takagi and Toru Miyoshi and Masayuki Doi and Keisuke Okawa and Kazumasa Nosaka and Tomoyuki Nishibe and Naoaki Matsuo and Satoshi Hirohata and Hiroshi Itoh",
year = "2017",
month = "10",
day = "10",
doi = "10.1186/s12872-017-0691-2",
language = "English",
volume = "17",
journal = "BMC Cardiovascular Disorders",
issn = "1471-2261",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention

AU - Takagi, Wataru

AU - Miyoshi, Toru

AU - Doi, Masayuki

AU - Okawa, Keisuke

AU - Nosaka, Kazumasa

AU - Nishibe, Tomoyuki

AU - Matsuo, Naoaki

AU - Hirohata, Satoshi

AU - Itoh, Hiroshi

PY - 2017/10/10

Y1 - 2017/10/10

N2 - Background: Adipocyte fatty acid-binding protein (A-FABP) is expressed in both adipocytes and macrophages. Recent studies have shown that A-FABP is secreted by adipocytes and that the A-FABP concentration is associated with obesity, insulin resistance, and atherosclerosis. We have reported that the coronary atherosclerotic burden is associated with the serum A-FABP concentration. In the present study, we investigated whether the serum A-FABP concentration is associated with prognosis in patients with stable angina pectoris who have undergone percutaneous coronary intervention (PCI). Methods: This was a prospective single-center trial. In total, 130 patients with stable angina pectoris undergoing their first PCI were enrolled from August 2008 to July 2010 at Kagawa Prefectural Central Hospital. The primary endpoints were cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, revascularization, and hospitalization for heart failure. Results: During the follow-up (median, 50months; interquartile range, 23-66months), 49 cardiovascular events occurred. Kaplan-Meier analysis showed that the cumulative incidence of the primary endpoints in the high A-FABP group (median A-FABP concentration of ≥18.6ng/ml) was greater than that in the low A-FABP group. Cox analysis showed that the A-FABP concentration was an independent predictor of cardiovascular events adjusted for age and the presence of multi-vessel disease (hazard ratio, 1.03; 95% confidence interval, 1.01-1.04; p=0.01). Conclusion: The serum A-FABP concentration is associated with prognosis in patients with stable angina undergoing PCI, suggesting that the serum A-FABP concentration could be useful for risk assessment of secondary prevention. Trial registration: UMIN Clinical Trials Registry UMIN000029283(registration date: September 25, 2017), retrospectively registered.

AB - Background: Adipocyte fatty acid-binding protein (A-FABP) is expressed in both adipocytes and macrophages. Recent studies have shown that A-FABP is secreted by adipocytes and that the A-FABP concentration is associated with obesity, insulin resistance, and atherosclerosis. We have reported that the coronary atherosclerotic burden is associated with the serum A-FABP concentration. In the present study, we investigated whether the serum A-FABP concentration is associated with prognosis in patients with stable angina pectoris who have undergone percutaneous coronary intervention (PCI). Methods: This was a prospective single-center trial. In total, 130 patients with stable angina pectoris undergoing their first PCI were enrolled from August 2008 to July 2010 at Kagawa Prefectural Central Hospital. The primary endpoints were cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, revascularization, and hospitalization for heart failure. Results: During the follow-up (median, 50months; interquartile range, 23-66months), 49 cardiovascular events occurred. Kaplan-Meier analysis showed that the cumulative incidence of the primary endpoints in the high A-FABP group (median A-FABP concentration of ≥18.6ng/ml) was greater than that in the low A-FABP group. Cox analysis showed that the A-FABP concentration was an independent predictor of cardiovascular events adjusted for age and the presence of multi-vessel disease (hazard ratio, 1.03; 95% confidence interval, 1.01-1.04; p=0.01). Conclusion: The serum A-FABP concentration is associated with prognosis in patients with stable angina undergoing PCI, suggesting that the serum A-FABP concentration could be useful for risk assessment of secondary prevention. Trial registration: UMIN Clinical Trials Registry UMIN000029283(registration date: September 25, 2017), retrospectively registered.

KW - Adipocyte

KW - Coronary artery disease

KW - Fatty acid

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=85030872144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030872144&partnerID=8YFLogxK

U2 - 10.1186/s12872-017-0691-2

DO - 10.1186/s12872-017-0691-2

M3 - Article

C2 - 29017449

AN - SCOPUS:85030872144

VL - 17

JO - BMC Cardiovascular Disorders

JF - BMC Cardiovascular Disorders

SN - 1471-2261

IS - 1

M1 - 258

ER -